

21 February 2024

Osteopore advances consolidation of capital to support long-term growth

Singapore-founded regenerative medicine company **Osteopore Limited (ASX: OSX or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – is pleased to announce that the Company's shareholders have approved a consolidation of capital.

The capital consolidation will streamline the Company's capital structure and support the business to continue delivering on its work plan while positioning the Company to maximise growth opportunities and shareholder value.

Osteopore's shareholders approved the consolidation based on a ratio of [15] to [1], which means that every [15] pre-consolidation securities will be consolidated into [1] post-consolidation security.

The consolidation – effective 5 March 2024 – was approved by shareholders at a General Meeting (GM) held in Perth, Western Australia at 10.00 am (WST) on 21 February 2024, where the resolution was passed by a poll vote.

The information required to be disclosed by the Company in accordance with ASX Listing Rule 3.13.2 and Section 251AA (2) of the Corporations Act 2001 (Cth) – is attached.

Following the completion of the capital consolidation, Osteopore's capital structure is expected to comprise approximately:

- 10,327,909 post-consolidation shares
- 3,522,527 post-consolidation options
- 900,000 post-consolidation performance rights

The Company believes the consolidation is another key step towards maximising shareholder value and capitalising on the exciting opportunities presented by regenerative medicine.



Commenting on the share consolidation Osteopore Executive Chairman Mark Leong said:

“The consolidation will streamline our capital structure and support the business to continue delivering on our growth strategy, laying the foundation for the right ecosystem to achieve revenue growth and shareholder returns.”

“Osteopore recognises the outstanding support of our shareholders, who understand the exciting potential of our Company and the regenerative medicine sector.”

ENDS

This announcement dated 21 February 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

T: +65 9011 7009

E: mark_leong@osteopore.com

Isaac Stewart

Media & Investor Relations

Cannings Purple

T: +61 423 306 795

E: istewart@canningspurple.com.au

About Osteopore Limited

Osteopore Limited is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The Company seeks to commercialise products that stimulate natural bone healing across multiple segments.

Osteopore creates patented scaffolds using 3D-printed biomimetic and bioresorbable materials to guide and nurture bone-forming cells.

Through our proprietary manufacturing process – which uses a naturally dissolving polymer – our patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.



Results of General Meeting

Name of entity

Osteopore Limited

ABN/ACN/ARSN/ARBN

630 538 957

Date of meeting

21 February 2024

Resolutions voted on at the meeting					If decided by poll					Proxies received			
Resolution		Result	Voting method	If s250U applies	Voted for		Voted against		Abstained*	For	Against	Abstain	Discretion
No	Short description				Number	%	Number	%	Number	Number	Number	Number	Number
1	Consolidation of capital	Passed	Poll	N/A	40,592,474	88.04	5,516,951	11.96	1,000	40,032,887	5,516,951	1,000	63,873

* Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item.